rs121908490
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_003919.3(SGCE):c.304C>T(p.Arg102Ter) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000248 in 1,611,212 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.000013 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0000014 ( 0 hom. )
Consequence
SGCE
NM_003919.3 stop_gained
NM_003919.3 stop_gained
Scores
5
1
1
Clinical Significance
Conservation
PhyloP100: 9.42
Genes affected
SGCE (HGNC:10808): (sarcoglycan epsilon) This gene encodes the epsilon member of the sarcoglycan family. Sarcoglycans are transmembrane proteins that are components of the dystrophin-glycoprotein complex, which link the actin cytoskeleton to the extracellular matrix. Unlike other family members which are predominantly expressed in striated muscle, the epsilon sarcoglycan is more broadly expressed. Mutations in this gene are associated with myoclonus-dystonia syndrome. This gene is imprinted, with preferential expression from the paternal allele. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. A pseudogene associated with this gene is located on chromosome 2. [provided by RefSeq, Oct 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 7-94628288-G-A is Pathogenic according to our data. Variant chr7-94628288-G-A is described in ClinVar as [Pathogenic]. Clinvar id is 5769.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr7-94628288-G-A is described in Lovd as [Pathogenic]. Variant chr7-94628288-G-A is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SGCE | NM_003919.3 | c.304C>T | p.Arg102Ter | stop_gained | 3/11 | ENST00000648936.2 | NP_003910.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SGCE | ENST00000648936.2 | c.304C>T | p.Arg102Ter | stop_gained | 3/11 | NM_003919.3 | ENSP00000497130 | A1 |
Frequencies
GnomAD3 genomes AF: 0.0000132 AC: 2AN: 151738Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
2
AN:
151738
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1459474Hom.: 0 Cov.: 30 AF XY: 0.00000138 AC XY: 1AN XY: 726024
GnomAD4 exome
AF:
AC:
2
AN:
1459474
Hom.:
Cov.:
30
AF XY:
AC XY:
1
AN XY:
726024
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000132 AC: 2AN: 151738Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74078
GnomAD4 genome
AF:
AC:
2
AN:
151738
Hom.:
Cov.:
32
AF XY:
AC XY:
0
AN XY:
74078
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:9
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Feb 01, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Aug 01, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jan 29, 2015 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Jul 28, 2021 | This variant is expected to result in the loss of a functional protein. This variant has not been reported in large, multi-ethnic general populations (http://gnomad.broadinstitute.org). This variant appears to segregate with disease in at least one family. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 03, 2024 | Published functional studies demonstrate a damaging effect and show that this variant interferes with SGCE gene expression (PMID: 28155872); Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25525159, 11528394, 12874409, 31440721, 36161439, 17853490, 22363319, 31338059, 34906973, 33022436, 35995778, 33808167, 18205193, 28155872) - |
Myoclonic dystonia 11 Pathogenic:3
Pathogenic, no assertion criteria provided | literature only | OMIM | Jul 22, 2003 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Jul 22, 2019 | This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 24, 2023 | This sequence change creates a premature translational stop signal (p.Arg102*) in the SGCE gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SGCE are known to be pathogenic (PMID: 12821748, 15389977, 17853490, 24297365). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with myoclonus–dystonia (PMID: 11528394, 12874409, 18205193). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 5769). For these reasons, this variant has been classified as Pathogenic. - |
SGCE-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Nov 14, 2023 | The SGCE c.304C>T variant is predicted to result in premature protein termination (p.Arg102*). This variant has been documented to be causative for myoclonus-dystonia syndrome (Zimprich et al. 2001. PubMed ID: 11528394). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. In ClinVar, this variant has been interpreted as pathogenic by multiple submitters (https://www.ncbi.nlm.nih.gov/clinvar/variation/5769/). Nonsense variants in SGCE are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
MutationTaster
Benign
A;A;A;A;A;A
Vest4
0.91, 0.91, 0.79, 0.79, 0.80, 0.82
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at